TATA-binding protein-associated factor 172
Cullin-7 (1271-1279) is a synthetic peptide fragment corresponding to amino acid residues 1271 through 1279 of the human Cullin-7 protein, a member of the cullin family of E3 ubiquitin ligase scaffold proteins. As a peptide compound, it serves as a valuable molecular tool for dissecting the structural and functional aspects of Cullin-7-mediated protein interactions and ubiquitin ligase activity. The C-terminal region of Cullin-7, from which this peptide is derived, is implicated in protein-protein interactions and regulatory processes essential for targeted protein degradation via the ubiquitin-proteasome pathway. The use of this defined peptide segment enables researchers to investigate specific binding motifs, post-translational modification sites, and the mechanistic basis of Cullin-7's involvement in cellular signaling and protein homeostasis.
Protein-protein interaction studies: The Cullin-7 (1271-1279) peptide is employed in in vitro binding assays to map interaction domains within the Cullin-7 protein and its partners. By providing a defined and isolated segment of the larger protein, the peptide allows researchers to delineate minimal binding motifs required for the recruitment of adaptor proteins, substrate receptors, or regulatory cofactors. Such studies are instrumental in unraveling the molecular determinants of Cullin-7's scaffolding function in multi-subunit E3 ubiquitin ligase complexes.
Ubiquitination pathway analysis: In the context of ubiquitin ligase research, this peptide fragment serves as a substrate or competitive inhibitor in assays designed to probe the specificity and efficiency of protein ubiquitination. Its defined sequence can be used to test the recognition and modification by E3 ligase machinery, thereby elucidating the sequence determinants that guide substrate selection and polyubiquitination. These insights contribute to a deeper understanding of regulated proteolysis and the control of protein turnover in eukaryotic cells.
Peptide-based inhibitor development: The Cullin-7 (1271-1279) segment provides a rational starting point for the design and screening of peptide-based inhibitors targeting Cullin-7 interactions. By mimicking critical binding interfaces, the peptide can be used to competitively block the association of Cullin-7 with its regulatory or substrate-binding partners in biochemical assays. Such applications are relevant for dissecting the functional consequences of disrupting Cullin-7-mediated ubiquitin ligase assembly and activity, and for validating potential therapeutic targets in the ubiquitin-proteasome system.
Antibody generation and epitope mapping: Researchers utilize this peptide as an immunogen or as a reference epitope in the production and validation of antibodies specific to the C-terminal region of Cullin-7. The defined sequence enables precise mapping of antibody binding sites, facilitating the development of high-affinity reagents for use in immunoprecipitation, Western blotting, or immunofluorescence. These antibodies are essential tools for monitoring Cullin-7 expression, localization, and post-translational modifications in diverse experimental systems.
Phosphorylation and post-translational modification studies: The Cullin-7 (1271-1279) peptide is also suitable for in vitro kinase assays and mass spectrometry-based analyses aimed at identifying and characterizing post-translational modifications within this region. By providing a controllable substrate, researchers can investigate the regulatory impact of phosphorylation, acetylation, or ubiquitination on Cullin-7's function and its interactions with other proteins. Such studies advance our understanding of the dynamic regulation of Cullin-7 and its broader implications in cellular signaling networks.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More